HC Wainwright & Co. Reiterates Buy on Crinetics Pharmaceuticals, Maintains $33 Price Target
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Douglas Tsao has reiterated a 'Buy' rating on Crinetics Pharmaceuticals (NASDAQ:CRNX) and maintained a price target of $33.
August 11, 2023 | 12:32 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Crinetics Pharmaceuticals (NASDAQ:CRNX) has had its 'Buy' rating reiterated by HC Wainwright & Co. with a maintained price target of $33.
The reiteration of a 'Buy' rating and maintenance of a $33 price target by HC Wainwright & Co. indicates a positive outlook for Crinetics Pharmaceuticals. This could potentially lead to an increase in investor confidence and a positive impact on the stock's short-term price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100